Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Work In Process (2023 - 2025)

Historic Work In Process for Maxcyte (MXCT) over the last 3 years, with Q3 2025 value amounting to $400000.0.

  • Maxcyte's Work In Process rose 3114.75% to $400000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $400000.0, marking a year-over-year increase of 3114.75%. This contributed to the annual value of $270000.0 for FY2024, which is 5161.29% down from last year.
  • Latest data reveals that Maxcyte reported Work In Process of $400000.0 as of Q3 2025, which was up 3114.75% from $337000.0 recorded in Q2 2025.
  • In the past 5 years, Maxcyte's Work In Process registered a high of $1.0 million during Q2 2023, and its lowest value of $101000.0 during Q2 2024.
  • Its 3-year average for Work In Process is $439927.3, with a median of $337000.0 in 2025.
  • As far as peak fluctuations go, Maxcyte's Work In Process crashed by 8993.22% in 2024, and later soared by 23366.34% in 2025.
  • Maxcyte's Work In Process (Quarter) stood at $558000.0 in 2023, then tumbled by 51.61% to $270000.0 in 2024, then surged by 48.15% to $400000.0 in 2025.
  • Its Work In Process was $400000.0 in Q3 2025, compared to $337000.0 in Q2 2025 and $199000.0 in Q1 2025.